These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37941470)

  • 1. Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study.
    Fernandez AP; Gallop J; Polly S; Khanna U
    Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37941470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.
    Aggarwal R; Marder G; Koontz DC; Nandkumar P; Qi Z; Oddis CV
    Ann Rheum Dis; 2018 May; 77(5):720-727. PubMed ID: 29237618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
    Ahmed S; Chakka S; Concha J; Krain R; Feng R; Werth VP
    Br J Dermatol; 2020 Apr; 182(4):949-954. PubMed ID: 31206600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.
    Anyanwu CO; Fiorentino DF; Chung L; Dzuong C; Wang Y; Okawa J; Carr K; Propert KJ; Werth VP
    Br J Dermatol; 2015 Oct; 173(4):969-74. PubMed ID: 25994337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
    Bitar C; Ninh T; Brag K; Foutouhi S; Radosta S; Meyers J; Baddoo M; Liu D; Stumpf B; Harms PW; Saba NS; Boh E
    JAMA Dermatol; 2022 Dec; 158(12):1357-1366. PubMed ID: 36197661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
    Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
    Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.
    Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW
    Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study.
    Werth VP; Aggarwal R; Charles-Schoeman C; Schessl J; Levine T; Kopasz N; Worm M; Bata-Csörgő Z
    EClinicalMedicine; 2023 Oct; 64():102234. PubMed ID: 37799613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
    Toyos M; Toyos R; Jodoin B; Bunch R
    Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.
    Tiao J; Feng R; Berger EM; Brandsema JF; Coughlin CC; Khan N; Kichula EA; Lerman MA; Lvovich S; McMahon PJ; Rider LG; Rubin AI; Scalzi LV; Smith DM; Taxter AJ; Treat JR; Williams RP; Yum SW; Okawa J; Werth VP
    Br J Dermatol; 2017 Oct; 177(4):1086-1092. PubMed ID: 28421601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
    Paik JJ; Casciola-Rosen L; Shin JY; Albayda J; Tiniakou E; Leung DG; Gutierrez-Alamillo L; Perin J; Florea L; Antonescu C; Leung SG; Purwin G; Koenig A; Christopher-Stine L
    Arthritis Rheumatol; 2021 May; 73(5):858-865. PubMed ID: 33258553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database.
    Pandya R; Kleitsch J; Lim D; Werth VP
    J Am Acad Dermatol; 2024 Jul; 91(1):31-36. PubMed ID: 38342246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.
    Tiao J; Feng R; Bird S; Choi JK; Dunham J; George M; Gonzalez-Rivera TC; Kaufman JL; Khan N; Luo JJ; Micheletti R; Payne AS; Price R; Quinn C; Rubin AI; Sreih AG; Thomas P; Okawa J; Werth VP
    Br J Dermatol; 2017 Feb; 176(2):423-430. PubMed ID: 28004387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 17. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
    Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
    Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
    Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
    Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.